Description
Latin name
Probifor
Release form
Powder for oral administration.
Packaging
30 sachets.
Pharmacological action
Probifor is a preparation of biological origin that regulates the balance of intestinal microflora, a probiotic.
The antidiarrheal effect of the drug is due to the high concentration of bifidobacteria adsorbed on activated carbon particles, which are antagonists of a wide range of pathogenic (including Shigella spp., Salmonella spp., Staphylococcus aureus) and conditionally pathogenic microorganisms (including Proteus spp., Klebsiella spp.).
The anti-infectious effect of the drug is enhanced by sorption of bifidobacteria on coal particles, which leads to an accelerated normalization of the digestive tract microbiocenosis, activation of recovery processes in the mucous membranes and an increase in the anti-infection resistance of the body.
The antitoxic effect of the drug is provided by the rapid colonization of the intestines with microcolonies of bifidobacteria, the restoration of normal microflora, which prevents the penetration of toxins into the internal environment of the body and, as a natural biosorbent, accumulates a significant amount of toxic substances that enter from the outside or are formed in the body.
Bifidobacteria in high concentration activate parietal digestion of the intestine, the synthesis of vitamins and amino acids, enhance the protective function of the intestine and the body’s immune defense.
Indications
Diarrhea of ² ¹ ² ¹various etiologies.
Foodborne Toxic Infection.
Acute intestinal infections of a bacterial and viral nature (salmonellosis, shigellosis, enterocolitis caused by pathogenic representatives of the genus enterobacteria or staphylococci, rotavirus infection) or an unknown etiology.
Dysbacterioses of various etiologies, including those developed during and after taking antibiotics, cytostatic, radiation therapy.
Complicating the course of viral hepatitis, cirrhosis of the liver, diverticulosis of the intestine of various localization.
Newborns (including premature infants) with a burdened premorbid background, starting from the period of stay in the maternity hospital, to improve the course of the adaptation period, as well as with severe dysbiosis.
Pregnant women in preparation for childbirth, cesarean section and in the postoperative period.
The drug is used as part of complex therapy:
Chronic infectious and non-specific inflammatory diseases of the digestive tract (gastroduodenitis, pancreatitis, proctosigmoiditis, colitis, including ulcerative colitis).
Patients (including newborns) with secondary immunodeficiency conditions, with severe infectious-inflammatory and purulent-septic diseases (sepsis, peritonitis, etc.).
Patients with skin diseases (atopic dermatitis, streptoderma, eczema).
Irritable bowel syndrome, other functional intestinal disorders.
Syndrome of impaired intestinal absorption of various etiologies.
Acute respiratory viral infections and flu.
Surgical patients (including trauma profile) for preoperative preparation and prevention of postoperative complications.
Surgical patients with post-gastro-resection disorders and conditions after cholecystectomy.
Oncological patients during chemotherapy, radiation therapy, before and after surgical interventions.
Contraindications
Congenital lactase deficiency.
Impaired absorption of glucose-galactose.
Use during pregnancy and lactation
Probifor is approved for use by women during pregnancy and breastfeeding.
Composition
Powder for oral administration.
Active substance:
bifidobacteria, sorbed on activated carbon not less than 500 million (5 Ã 108) CFU.
Excipient:
lactose monohydrate – up to 0.85 g.
Storage conditions
Store in a dry place, at a temperature not exceeding 10 ° C. The lower temperature limit is not limited. Transportation at temperatures above 25 ° C is allowed for no more than 10 days.
Expiration
2 years.
Dispensing conditions from pharmacies
Over-the-counter
partner, Russia
